Company: IMCR
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001671927-25-000009
Chunk: 32

Company: Immunocore Holdings plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 32
---
 The Company manages its business activities on a consolidated basis. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM"), the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The measure of the segment profit or loss used is consolidated net income (loss), and the measure of segment assets is reported on the condensed consolidated balance sheet as total assets. The accounting policies of the immunotherapies segment are the same as those described in Note 2. "Summary of significant accounting policies". The following table summarizes the reportable segment's financial information (in thousands):Three Months Ended March 31,20252024Revenue$93,881 $70,502 Less:Cost of revenue from sale of therapies(831)(246)External research and development (R&D) expenses:PRAME programs(17,305)(26,700)Tebentafusp programs(7,990)(5,894)Infectious disease programs(1,405)(2,246)All other external clinical and preclinical costs(11,231)(6,499)Total external R&D expenses(37,931)(41,339)R&D salaries and other employee-related costs(11,043)(9,754)Selling, general and administrative (SG&A) salaries and other employee-related costs(12,218)(14,840)Other SG&A expenses(20,672)(17,463)Other segment expense, net (a)(6,163)(11,296)Segment and consolidated net income (loss) $5,023 $(24,436)

(a) Other segment expenses, net includes other internal R&D expenses, share-based compensation expense, R&D tax credits, interest income, interest expense, foreign currency gain (loss), other income (expense), net and income tax expense.

10. Commitments and contingencies

Lease commitments The maturities of operating lease liabilities as of March 31, 2025 were as follows (in thousands):2025$3,569 20264,941 20274,836 20285,094 20294,943 2030 and thereafter46,365 Total lease payments69,748 Less imputed interest(27,283)Present value of operating lease liabilities$42,465 

14

Manufacturing commitmentsThe Company enters into a number of manufacturing commitments for the future purchase of materials and contract manufacturing services. While the majority of